Clinical Trial Update: A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing bioequivalence of 20 mg subcutaneous ofatumumab delivered via pre-filled syringe vs autoinjector in adults with relapsing forms of multi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ofatumumab (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2020-10-09